Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Tickers GLUE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.